Loading...
Loading...
Lexicon Pharmaceuticals LXRX shares are trading higher on Tuesday after the company's SOLOIST and SCORED Phase 3 studies achieved their primary endpoints.
Lexicon Pharmaceuticals is a company developing medicines that transform patients' lives. The company commercializes and develops drugs and drug candidates.
Lexicon Pharmaceuticals shares were trading up 43.02% at $1.84 on Tuesday during the time of publication. The stock has a 52-week high of $5.33 and a 52-week low of $1.03.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in